奥西默替尼
蛋白激酶B
PI3K/AKT/mTOR通路
突变
癌症研究
医学
后天抵抗
生物
遗传学
肿瘤科
内科学
癌症
基因
磷酸化
表皮生长因子受体
信号转导
埃罗替尼
作者
Natalie I. Vokes,Xiuning Le,Timothy A. Yap
标识
DOI:10.1158/1078-0432.ccr-24-1188
摘要
A recent study identified high rates of PI3K-AKT pathway mutations from the FLAURA and AURA3 osimertinib trials and pre-clinically validated that these mutations decreased osimertinib sensitivity in EGFR-mutated non-small cell lung cancer. The AKT inhibitor capivasertib was found to overcome this resistance, providing an important rationale for the development of AKT inhibitors in non-small cell lung cancer. See related article by Grazini et al., p. 4143.
科研通智能强力驱动
Strongly Powered by AbleSci AI